E*TRADE Financial Corporation (ETFC) had a light trading with around 2.13M shares changing hands compared to its three month average trading volume of 2.89M. The stock traded between $29.38 and $29.92 before closing at the price of $29.41 with -0.51% change on the day. The New York New York 10020 based company is currently trading 49.97% above its 52 week low of $19.61 and -5.07% below its 52 week high of $30.98. Both the RSI indicator and target price of 68.48 and $30.8 respectively, lead us to believe that it should be put on hold over the coming weeks.
E*TRADE Financial Corporation, a financial services company, provides brokerage and related products and services primarily to individual retail investors under the E*TRADE Financial brand name. It operates through two segments, Trading and Investing, and Balance Sheet Management. The Trading and Investing segment offers retail brokerage products and services, investor-focused banking products, and corporate services. The Balance Sheet Management segment manages asset allocation; loans previously originated by the company or purchased from third parties; deposits and customer payables; and credit, liquidity, and interest rate risk. The company provides its services to customers through digital platforms; and a network of customer service representatives and financial consultants through phone, email, and online at two branches, as well as in person through 30 branches across the United States. E*TRADE Financial Corporation was incorporated in 1982 and is headquartered in New York, New York.
Quanta Services, Inc. (PWR) managed to rebound with the stock climbing 0.88% or $0.25 to close the day at $28.76 on active trading volume of 2.13M shares, compared to its three month average trading volume of 1.99M. The Houston Texas 77056 based company has been outperforming the general contractors group over the past 52 weeks, with the stock gaining 8.49%, compared to the industry which has dropped -1.11% over the same period. With RSI of 77.04, the stock should still continue to rise and get closer to its one year target estimate of $27.46, making it a hold for now.
Quanta Services, Inc. provides specialty contracting services to the electric power, and oil and gas industries in North America and internationally. The company operates through two segments, Electric Power Infrastructure Services and Oil and Gas Infrastructure Services. The company’s Electric Power Infrastructure Services segment provides network solutions comprising design, installation, upgrade, repair, and maintenance of electric power transmission and distribution infrastructure, and substation facilities. It also provides emergency restoration services, including the repair of infrastructure. In addition, this segment designs, installs, and maintains renewable energy generation facilities comprising solar, wind, and various types of natural gas generation facilities, as well as related switchyards and transmission infrastructure to transport power; and commercial and industrial wiring. Further, it installs traffic networks; cable and control systems for light rail lines; and ancillary telecommunication infrastructure services. The company’s Oil and Gas Infrastructure Services segment provides network solutions to customers involved in the development and transportation of natural gas, oil, and other pipeline products. Its services include the design, installation, repair, and maintenance of pipeline transmission and distribution systems, gathering systems, production systems, and compressor and pump stations, as well as related trenching, directional boring, and automatic welding services. This segment also provides pipeline protection; integrity testing; rehabilitation and replacement; fabrication of pipeline support systems, and related structures and facilities; and infrastructure services for the offshore and inland water energy markets. In addition, it designs, installs, and maintains fueling systems, as well as water and sewer infrastructure. The company was founded in 1997 and is headquartered in Houston, Texas.
Celldex Therapeutics, Inc. (CLDX) shares were up in last trading by 2.42% to $4.24. It experienced lighter than average volume on day. The stock increased in value by almost 6% over the past week and grew 22.9% in the past month. It is currently trading 6.69% above its 50 day moving average and -23.71% below its 200 day moving average. Following the recent increase in price, the stock’s new closing price represents a -77.23% decrease in value from its one year high of $18.62. The RSI indicator value of 57.11, lead us to believe that it is a hold for now.
Celldex Therapeutics, Inc., a biopharmaceutical company, develops, manufactures, and commercializes novel therapeutics for human health care in the United States. The company’s lead drug candidates comprise Rintega (CDX-110), a therapeutic vaccine in Phase III clinical studies for the treatment of glioblastoma patients that express an epidermal growth factor receptor variant III, as well as in Phase II study for the treatment of recurrent glioblastoma; Glembatumumab vedotin (CDX-011), a targeted antibody-drug conjugate (ADC) in a randomized Phase IIb study for the treatment of triple negative breast cancer, as well as in Phase II study for the treatment of metastatic melanoma; and Varlilumab (CDX-1127), an immune modulating antibody is in Phase I study for the treatment of multiple solid tumors. It also has various earlier stage drug candidates in clinical development, including CDX-1401, a targeted immunotherapeutic aimed at antigen presenting cells for cancer indications; CDX-301, an immune cell mobilizing agent and dendritic cell growth factor; and CDX-014, a fully-human monoclonal ADC that targets T cell immunoglobulin and mucin domain 1, a molecule, which is upregulated in various cancers comprising renal cell and ovarian carcinomas. It has research collaboration and license agreements with Medarex, Inc.; Rockefeller University; Duke University Brain Tumor Cancer Center; Ludwig Institute for Cancer Research; Alteris Therapeutics, Inc.; University of Southampton; Amgen Inc.; Amgen Fremont; and Seattle Genetics, Inc., as well as clinical trial collaboration with Roche Holding. The company is headquartered in Hampton, New Jersey.